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Abstract: With the technological advancements in the medical imaging field, the past decade has witnessed a 
dramatic evolution of multimodality imaging systems. Scientists, technologists and researchers have been able to 
bring systems in clinical practice, in which two or more standalone diagnostic imaging modalities have been 
combined. Some of those multimodality imaging systems are: PET/CT, SPECT/CT, PET/MRI and 
PET/SPECT/CT. With this technique a patient is scanned in a single session and the desired structural and 
functional information of the organ of interest is achieved. Recent clinical imaging studies in the areas of 
cardiology, endocrinology, infection, musculoskeletal and neurology has shown, that with multimodality diagnostic 
imaging, a significant increase in diagnostic accuracy is achieved, as compared to single diagnostic imaging 
modality. In this review, emphasis is given to the technical aspects and clinical applications of the SPECT/CT 
hybrid imaging modality. 
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I.   INTRODUCTION 
Imaging technological advancement has always been challenging to practitioners how best to optimize them in patient 
care. Correlative study has long been in use in clinical practice especially in the interpretation of images in nuclear 
medicine due to major limitations of morphological localization, poor spatial resolution and tissue attention [1]. 
Physicians have been well aware of the effectiveness in joining anatomical and physiological imaging five decades ago 
[2], [3]. The most significant diagnostic imaging technological progression to date is hybrid or fusion imaging, where 
morphology is merged with physiology resulting in a superior diagnostic tool capable of providing morphological and 
physiological information in one examination [3]. Earlier, the method of comparison of software co-registration were 
utilized but were limited by technical problems relating to difference in patient positioning, geometries of imaging 
equipment and displacement of movable structures between studies [1]. The real break-through in this field came, which 
caught the attention of medical imaging fraternity worldwide, with the development of computed tomography and hybrid 
positron emission tomography (PET). The PET/CT innovation has been so successful that major medical imaging 
manufacturers do not offer stand-alone PET scanners. Spurred by this success, SPECT/CT has presently been 
implemented in the nuclear medicine fraternity compelled by the advantages posed through their experiences with 
PET/CT. The unveiling of the positron emission tomography and magnetic resonance imaging (PET/MRI) further added 
impetus to hybrid imaging and the introduction of prototype PET/MRI devices [1], [3]. Hybrid imaging has few reasons 
behind its acceptance such as the high level of provision in diagnostic information from an examination, better liaising 
among clinicians and high specificity [4]. The molecular characterization attained via PET and SPECT has taken these 
imaging techniques to compliment diagnostic information particularly for cancer evaluation thereby making hybrid 
imaging the primary diagnostic tool in the new era of cancer imaging [1]. However, in this review, emphasis is given to 
the clinical applications and the technical aspects of the SPECT/CT hybrid modality.  
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II.    TECHNICAL ASPECTS OF SPECT/CT 
Single photon emission computed tomography (SPECT) is based on the determination of the concentration of 
radionuclide tracer over time and space in the organ of interest. As a result, visualization of dynamic physiological and 
patho-physiological process that identifies the functional characteristics of disease is achieved. On the contrary, images on 
SPECT do not achieve precise anatomic landmarks for accurate localization and classification of the results. CT diagnoses 
and characterizes the disease on the basis of morphologic criteria. This provides the information relating to the variations 
in the size of organ, and the density of tissue as well as their accurate localization and topographic landmarks. However, 
morphological data do not in essence show a relationship with the metabolic standing of the disease. Reporting suggest 
the change from SPECT alone to the combination of SPECT/CT could make diagnosis difference in 30% of the cases. 
Furthermore, SPECT/CT data has proven to be useful for guiding surgical procedures or in finding the target volume for 
external beam radiotherapy. Though both techniques, SPECT and CT have individually proved to be of good diagnostic 
performance it has become very imperative to shift the paradigm of standalone diagnostic imaging modality to hybrid 
imaging for more accurate diagnosis and treatment of disease. Integrating CT into SPECT has proved to be worthy 
diagnostic tool in medical imaging in which anatomical details may delineate functional and metabolic information. The 
SPECT/CT multimodality imaging concept is based on early attempt of localization of radionuclide tracer distribution by 
achieving morphological information in a single imaging system by using transmission sources in CT [5]. Hybrid imaging 
is technically more challenging and complex but provides useful information for some procedures along with patient 
examinations. An often overlooked advantage is that CT data is used for SPECT and PET images for attenuation 
correction [5] and scatter [6] as well as aiding in the correction of the partial volume effect, especially in tumors [7].  
Hasegawa and his colleagues developed the first commercial prototype SPECT/CT imaging system at the University of 
San Francisco with sponsorship from General Electric Healthcare (GE Healthcare). The equipment was a dual head with a 
variable geometry coupled in a single gantry to an X-ray source of 140 keV and 2.5mA with a sliding ring detector. The 
same patient couch for data acquisition of emission and transmission images was used by keeping in view the axial 
displacement between CT and SPECT imaging field. After the introduction of radionuclide into the patient, CT images 
were taken during the radionuclide uptake period and then SPECT data were collected. The CT data were utilized to 
produce attenuation coefficient map for SPECT image data to correct for attenuation of gamma photon effects. A number 
of clinical studies were performed with this integrated instrument particularly that of quantitative estimation of radiation 
dosimetry in brain tumor patients [8], [9]. 
Later Siemens and Philips brought the SPECT/CT integrated imaging equipment, In 2004 Siemens introduced Symbia 
series and Philips followed by introducing Precidence. Current SPECT/CT systems include that of Discovery NM/CT 670 
(General Electric), Symbia T Series (Siemens), and BrightView X/CT (Philips). The CT equipment is able to operate at a 
low tube current if it is used mainly for attenuation correction [5]. This then enhanced lesion localization, thus improving 
the overall image quality. Early CT component of combined imaging systems were available with various number of CT 
slice choices and with variable tube currents. The 64-slice CT cardiac, SPECT/CT provided excellent morphological 
functional quality by utilizing short scanning time, thereby eradicating patient movement artifacts in the image.  
Recently SPECT/CT has emerged as a diagnostic imaging tool with high potential in medical imaging. It facilitates to 
delineate the morphological details from the functional information in the image. Due to this advantage, the utility of 
SPECT/CT has largely increased in a number of clinical examinations especially in fields such as endocrinology, 
oncology, cardiology, musculoskeletal, infection and other areas. 
III.    CLINICAL APPLICATIONS OF SPECT/CT 
3.1 Cardiology 
For a patient with coronary artery disease (CAD), its diagnostic and the prognostic evaluation requires, myocardial 
perfusion scans by injecting Tl-201, Tc99m–Sestamibi, Tc99m tetrofosmin radiotracers. The functional severity of 
angiographically significant stenosis was defined. Attenuation of gamma photon hampers the specificity and limits the 
diagnostic accuracy. Furthermore, dual-modality SPECT/CT assists much better to correct the SPECT data for attenuation 
using the CT data for attenuation coefficient maps as compared to common attenuation correction techniques. Hence, 
diagnostic accuracy is improved by a proper assessment of the diaphragmatic surface. Nonetheless, in apex and left 
ventricle anterior wall, false positive spurious perfusion defects may appear due to the respiratory and cardiac motion 
[10]. 
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3.2 Thyroid Cancer 
Iodine-131 planar imaging for thyroid cancer is excellent in diagnosing recurrent or metastatic disease but lacks in 
accurately locating the disease [11]. SPECT/CT enhances variation between physiological and pathological uptake of the 
iodine in the whole body scan [12] which have a significant bearing on the treatment approach in patients [13]. Alongside 
providing information by the Iodine-131 scan, the CT contributes significantly in the detection of lung nodules, lytic bone 
lesions and lymph node metastases. Therefore, the specificity of the method increases where faults resulted from the 
physiological elimination of radiopharmaceutical are corrected [14] and confirmed with researchers in Europe reporting 
incremental value of SPECT/CT by 57% [11]. However to the extent which these outcomes improve patient management 
is still unclear [5]. 
3.3 Neuroendocrine Tumours, Neural Crest Tumours 
In neuro-endocrine tumor patient studies, SPECT/CT imaging allows the eradication of the physiological ambiguity of 
radiopharmaceutical (source of false positive) with CT providing better anatomic localization of the SPECT lesions [15], 
[16]. The addition of 40% of relevant clinical information using SPECT/CT was reported over the usage of SPECT alone 
[17]. However, the difficulty of false negative SPECT findings can’t be delineated due to the inborn low resolution and 
scarcity of intravenous and oral contrast in the CT component. A high end CT component is suggested to be put into 
effect in the SPECT/CT device in order to allow high quality contrast enhanced CT image acquisition in addition to 
SPECT [5]. Neural crest tumours like neuroblastoma, ganglioblastoma and pheochromocytoma, Iodine-123 or Indium-
131 MetaIodo Benzyl Guanithidine (MIBG) scintigraphy is utilized for primary tumour localization and monitoring 
metastatic spread pattern with overall high sensitivity of 92% and specificity of 96% [3] and similar to that of attained by 
PET/CT with Carbon-11-HED as tracer [18]. A substantial role of SPECT/CT in the healing management of 
neuroendocrine tumours was also reported in 14% of patients [11]. 
3.4 Lymphoscintigraphy 
The sensitivity of SPECT/CT is increased compared to that of SPECT alone as it lacks in anatomical landmarks [5]. 
Diagnostic efficacy in pilot studies using SPECT/CT was found to increase compared to that of SPECT in various 
cancers; melanoma [19], head and neck cancer [20], cervical cancer [21], invasive urinary bladder cancer [22], breast 
cancer [23] and prostate cancer [24]. 
3.5 Prostate Cancer 
Indium-111-Capromab-pendetide (ProstaScint) is seen as a reliable monoclonal antibody imaging agent for the detecting 
local or nodal occurrence in planar and SPECT imaging. However, poor spatial contrast and suboptimal quality of the 
images together with lack of anatomical landmarks has limited it from being used widespread [25], [5]. Though, with the 
advent of SPECT/CT, ProstaScint imaging has indicated notable incremental diagnostic value for clinical implication for 
diagnosis and mapping for planning of external radiation therapy [26], [27]. 
3.6 Bone Scintigraphy  
Presently SPECT/CT has added diagnostic information by improving localization and classification of bone lesions. 
Sensitivity and specificity of SPECT/CT is primarily achieved by detecting benign bone conditions with increased bone 
turnover [10]. However, no additional benefit had been confirmed over the visual fusion of bone SPECT with planar X-
ray, CT or MRI. SPECT/CT has the disadvantage of increased radiation dose. In contrast, low dose SPECT/CT may miss 
osteolytic lesions [28]. A better solution in solving the problem could be by employing SPECT guided CT that is 
maintained by the hybrid system [29]. 
3.7 Infections 
Gallium-67 scintigraphy, Indium-111 and Technetium-99m labelled white blood cell scintigraphy are mainly used in the 
visualization of infection. Physiological uptake and excretion together with poor topographical information may hamper 
scan information [30]. SPECT/CT has proved to be useful in providing improved diagnostic information, better 
localization and in evaluating extent of infection [31], [32].   
3.8 Skeletal Imaging 
The role of SPECT/CT in skeletal evaluation is invaluable. The technology not only has enabled accurate localization but 
has also improved specificity with CT information [5]. SPECT/CT has proved to be a useful imaging tool in localizing 
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active arthritis, particularly in areas where the configuration and number of joints is intricate [33]. This multimodality 
imaging is also ideal for the detection of complications in patients arising from bone injuries such as chronic regional pain 
syndrome and nonunion with more convincing accuracy [34]. 
IV.    CONCLUSION 
The hybrid imaging technique (SPECT/CT) in clinical applications has substantially reduced the number of false-negative 
results and increased the number of true-positive results. Information extracted from multimodality images may contribute 
to the development of a specific treatment plan that can lead to the best possible care for each individual patient – 
personalized treatment. In the future more multimodality imaging techniques may appear with various combinations of 
standalone diagnostic imaging modalities. This may further revolutionize the diagnostic imaging procedures and will have 
a tremendous impact on the management of patients and ultimately will synergize the healthcare in particular and research 
in general. 
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